Recruiting studies: Idh1 Gene Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelod
Phase 3 · 62 location(s) · Institut de Recherches Internationales Servier · NCT06465953 Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Phase 2 · 1 location(s) · Timothy Pardee · NCT07471841 Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treat
Phase 3 · 114 location(s) · Servier Bio-Innovation LLC · NCT06127407 ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
Phase N/A · 1 location(s) · CHA University · NCT07151118 a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07007949 Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC
Phase N/A · 1 location(s) · CHA University · NCT07142226 Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
Phase 1 · 2 location(s) · City of Hope Medical Center · NCT06543381 Study of Olutasidenib and Temozolomide in HGG
Phase 2 · 20 location(s) · Rigel Pharmaceuticals · NCT06161974 A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) M
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05588141 Ivosidenib as Post-HSCT Maintenance for AML
Phase 2 · 6 location(s) · Massachusetts General Hospital · NCT06707493 Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Meta
Phase 1/Phase 2 · 38 location(s) · Institut de Recherches Internationales Servier · NCT06501625 Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06611839 Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Phase 1 · 30 location(s) · Institut de Recherches Internationales Servier · NCT02074839 Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemi
Phase N/A · 13 location(s) · iOMEDICO AG · NCT06607302 Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute M
Phase 2 · 12 location(s) · Technische Universität Dresden · NCT06717958 Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
Phase 1 · 1 location(s) · University of Chicago · NCT06291987 Chronic CED of TPT for Recurrent Malignant Glioma
Phase 1 · 1 location(s) · Jeffrey N. Bruce · NCT06666712 CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04493164 An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m
Phase 3 · 15 location(s) · Servier Affaires Médicales · NCT05907057 A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia
Phase 2 · 1 location(s) · Kissei Pharmaceutical Co., Ltd. · NCT07604064 Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Phase 4 · 2 location(s) · Rigel Pharmaceuticals · NCT07486713 Diagnostic and Therapeutic Targets in Cartilaginous Tumours
Phase N/A · 1 location(s) · St. Anne's University Hospital Brno, Czech Republic · NCT07315542 A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Phase 1 · 15 location(s) · Nuvectis Pharma, Inc. · NCT05873686 Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I
Phase 2 · 1 location(s) · Justin Watts, MD · NCT06782542

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.